Cytovia Therapeutics
MA - CambridgeBiotechnology
Focus: Cytovia Therapeutics is a Cambridge-based biotech focused on bispecific antibody and iPSC-derived, TALEN gene-edited NK-cell platforms for cell therapy. The company operates at pre-revenue stage with a single clinical program.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Cytovia Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Cytovia Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
histamine dihydrochloride and IL-2
Acute Myeloid LeukemiaClinical Trials (1)
NCT01347996Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
Phase 4Help build intelligence for Cytovia Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.